Assay News and Research

RSS

University of Washington partners with USAID to better identify and prevent future pandemics

Randy CarnellLaboratory medicine scientists look through the window of equipment used in analyzing virus samples.

6 Oct 2021

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

A new study shows that up to a third of survivors in LTCFs were infected during the first year after infection.

5 Oct 2021

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

One recent study assessed the serum of Beta variant infected patients to determine whether major non-VOC antibodies could neutralize this virus.

5 Oct 2021

What makes SARS-CoV-2 variants more virulent?

Researchers in the Republic of Korea have conducted a study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that could help to inform further studies investigating the increased virulence of variants of concern and interest.

4 Oct 2021

How durable is the immune response generated from the BNT162b2 vaccine?

In a recent study, researchers analyzed antibody responses to the homologous Wu strain and several other SARS-CoV-2 variants after BNT162b2 vaccination.

4 Oct 2021

Antibody kinetics after natural SARS-CoV-2 infection and COVID-19 vaccination in Hispanic/Latino population

A new study addressing this issue has been published in Viruses that shows that functional neutralizing antibody tests are more relevant indicators than the presence or absence of binding antibodies.

4 Oct 2021

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

A new preprint deals with the analysis of the monoclonal antibody J08, which was capable of powerful neutralization of the wildtype SARS-CoV-2, and its VOCs.

1 Oct 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

Researchers develop fluorescence quenching assay to probe the integrity of cell membrane coating

Cell membrane coated biomimetic nanoparticles (NPs) have been widely studied in nanomedicine because of their unique properties such as immune escaping, long blood circulation, specific molecular recognition and efficient cancer targeting, indicating a great potential in targeted cancer therapy.

30 Sep 2021

SARS-CoV-2 nucleocapsid antigen as a possible COVID-19 severity marker

French researchers used a highly sensitive and specific nucleocapsid-Ag assay to explore the relationship between N-Ag in urine during COVID-19 and the severity of the disease in hospitalized patients.

30 Sep 2021

Gyros Protein Technologies introduces Gyrolab AAV9 Titer Kit to support AAV-based cell and gene therapy production

Gyros Protein Technologies AB today announced the introduction of Gyrolab® AAV9 Titer Kit for rapid determination of titer in AAV9 vector-based cell and gene therapy manufacturing.

From Gyros Protein Technologies AB 30 Sep 2021

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

A new study aimed to determine the course of SARS-CoV-2 infection in children suffering from rheumatic disease and were receiving bDMARD treatment.

29 Sep 2021

Highly Reproducible & Efficient Phospholipid Removal

Porvair Sciences has introduced a new and improved version of its Microlute® PLR phospholipid removal microplate designed to enhance the flow of samples through a proprietary filter to maximise the recovery of analytes with unmatched reproducibility.

From Porvair Sciences Limited 28 Sep 2021

Hamilton and Rhinostics Reinvent Rapid Swab-Based Sample Workflows from Collection to Processing

Hamilton Company and Rhinostics are combining their respective strengths to improve the speed and quality of nasal and nasopharyngeal sample workflows.

From Hamilton Process Analytics 28 Sep 2021

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

In a study conducted at the European Institute of Oncology, scientists have found that the risk and duration of SARS-CoV-2 infection reduced significantly after COVID-19 vaccination.

28 Sep 2021

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Sep 2021

Assay News and Research

University of Washington partners with USAID to better identify and prevent future pandemics

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

What makes SARS-CoV-2 variants more virulent?

How durable is the immune response generated from the BNT162b2 vaccine?

Antibody kinetics after natural SARS-CoV-2 infection and COVID-19 vaccination in Hispanic/Latino population

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

Novel Assay Platform for 3D Microfluidic Cancer Research

Researchers develop fluorescence quenching assay to probe the integrity of cell membrane coating

SARS-CoV-2 nucleocapsid antigen as a possible COVID-19 severity marker

Gyros Protein Technologies introduces Gyrolab AAV9 Titer Kit to support AAV-based cell and gene therapy production

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

Highly Reproducible & Efficient Phospholipid Removal

Hamilton and Rhinostics Reinvent Rapid Swab-Based Sample Workflows from Collection to Processing

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

New study clears a pharmacologic hurdle in developing molecularly targeted therapies for AML

Chronic COVID-19 and divergent variants of SARS-CoV-2

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

Researchers develop new method for rapidly detecting SARS-CoV-2 RNA

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News